% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Thomas:298170,
      author       = {M. Thomas and P. Christopoulos$^*$ and W. T. Iams and J.
                      Mazières and A. B. Cortot and N. Peled and G. Minuti and E.
                      F. Smit and F. Audhuy and K. Berghoff and S. P. Eggleton and
                      F. Fries and M. Hildenbrand and P. Liu and S. H. Mahmoudpour
                      and C. Menzel and D. Oksen},
      title        = {{MOMENT} registry: {P}atients with advanced non-small-cell
                      lung cancer harboring {MET} exon 14 skipping treated with
                      systemic therapy.},
      journal      = {Journal of Comparative Effectiveness Research},
      volume       = {14},
      number       = {2},
      issn         = {2042-6305},
      address      = {Royston, UK},
      publisher    = {Becaris Publishing},
      reportid     = {DKFZ-2025-00189},
      pages        = {e240127},
      year         = {2025},
      note         = {2025 Feb;14(2):e240127},
      abstract     = {Aim: MET exon 14 (METex14) skipping occurs in $3-4\%$ of
                      non-small-cell lung cancer (NSCLC) cases. Low frequency of
                      this alteration necessitated open-label, single-arm trials
                      to investigate MET inhibitors. Since broad MET biomarker
                      testing was only recently introduced in many countries,
                      there is a lack of historical real-world data from patients
                      with METex14 skipping NSCLC receiving conventional
                      therapies. Given the rarity of this population and
                      limitations of existing real-world data sources, the MOMENT
                      registry aims to prospectively collect uniform,
                      comprehensive, high-quality data from patients with METex14
                      skipping advanced NSCLC treated in routine clinical
                      practice, which can support clinical and regulatory decision
                      making. Patients $\&$ methods: MOMENT is a multinational,
                      non-interventional disease registry collecting data on
                      patients with METex14 skipping advanced NSCLC receiving any
                      systemic anticancer therapy. Newly diagnosed patients and
                      those already receiving treatment are eligible. Patients
                      with previous participation in a clinical trial can be
                      included if they receive at least one subsequent therapy
                      line in a routine clinical setting. Eligible systemic
                      treatment includes all available anticancer therapies
                      (approved, conditionally approved or provided through Early
                      Access). Data collection includes biomarker testing results,
                      demographics, baseline clinical characteristics, treatment
                      details and effectiveness, safety information and imaging.
                      Registry site inclusion is dependent on confirmation that
                      local METex14 skipping detection methods are sufficient to
                      confirm METex14 skipping status. MOMENT is currently active
                      at more than 60 sites across Europe and North America and
                      approximately 700 patients are expected to be enrolled
                      within the next 4 years. The first patient was enrolled on 4
                      October 2022. After completion of data collection, MOMENT
                      data can be shared with external parties to conduct
                      non-interventional studies. Discussion/conclusion: The
                      MOMENT registry collects comprehensive, high-quality
                      real-world data from patients with METex14 skipping advanced
                      NSCLC receiving systemic anticancer treatment in a routine
                      clinical setting, to enable future studies informing
                      regulatory decisions and optimal care for this rare
                      population. Clinical Trial Registration: NCT05376891
                      (ClinicalTrials.gov); EUPAS47602 (EU PAS register no.).},
      keywords     = {METex14 skipping (Other) / NSCLC (Other) / cancer registry
                      (Other) / real-world data (Other) / targeted therapy
                      (Other)},
      cin          = {B063},
      ddc          = {610},
      cid          = {I:(DE-He78)B063-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39836056},
      doi          = {DOI:10.57264/cer-2024-0127},
      url          = {https://inrepo02.dkfz.de/record/298170},
}